Industry Educational Session - Optimising BCMA-Directed Bispecific Therapies for Relapsed Refractory Multiple Myeloma Across Diverse Clinical Settings - Sponsored by Pfizer
Tracks
-
| Sunday, April 27, 2025 |
| 1:25 PM - 2:10 PM |
| M2 & M3 |
Details
Join leading experts Dr. Rakesh Popat, Dr. Jonathan Jones, and Dr. Jennifer Travers for an in-depth discussion on the application of BCMA-directed bispecific therapies in the management of relapsed/refractory multiple myeloma (RRMM). This educational session will explore variations in local recommendations across the UK and their impact on clinical practice, while delving into critical topics such as addressing system capacity challenges through ambulatory care models, implementing bispecific therapies in district general hospitals, and the essential role knowledge dissemination plays in these. Drawing on real-world clinical experience, the session provides actionable insights into integrating these innovative therapies into practice.
Speaker
Dr John Jones
King’s College Hospital, London
- Consultant Haematologist and Clinician Scientist specialising in myeloma. He undertakes clinical work at King’s College Hospital, London and Eastbourne District General Hospital.
Dr Rakesh Popat
Consultant Haematologist
University College London Hospitals NHS Foundation Trust
- Associate Professor at University College London and Consultant Haematologist at University College London Hospitals with an interest in multiple myeloma.
Dr Jennifer Travers
Consultant
Beatson West of Scotland Cancer Centre
- Consultant Haematologist at the Beatson West of Scotland Cancer Centre Glasgow, with a specialist interest in plasma cell disorders and PI for several myeloma trials. Other responsibilities include Haematology Clinical Lead and Laboratory Director at the Golden Jubilee National hospital in Glasgow.
